Baseline Characteristics of 116 Patients with NENs
| Characteristic | Data |
|---|---|
| Mean age (y) | 62.2 (SD, 10.8) |
| Sex | |
| Male | 64 (55) |
| Female | 52 (45) |
| Median Ki-67* (%) | 5 (range, 1–100) |
| World Health Organization grade† | |
| G1 | 27 (23) |
| G2 | 79 (68) |
| G3 | 4 (3) |
| Missing | 6 (5) |
| Site of primary | |
| Small intestine | 66 (57) |
| Pancreas | 25 (22) |
| Cecum | 7 (6) |
| Extrahepatic biliary tract | 2 (2) |
| Gastric | 1 (1) |
| Lung | 5 (4) |
| Unknown primary NEN | 10 (9) |
| Treatment before 64Cu-DOTATATE PET/CT‡ | |
| None | 15 (13) |
| Localized | 10 (8) |
| Systemic | 43 (37) |
| Localized and systemic | 48 (41) |
↵* Missing for 6 patients.
↵† Patients with lung NENs had Ki-67 < 10% and were accordingly placed in G1 and G2.
↵‡ Localized treatment for NENs: surgery (n = 52), hepatic artery embolization (n = 7), radiofrequency ablation (n = 7), or external radiation (n = 2). Systemic treatment for NENs: interferon (n = 52), somatostatin analog (n = 47), chemotherapy (n = 48), or peptide receptor radionuclide therapy (n = 36).
Data are number followed by percentage in parentheses, unless otherwise indicated. Percentages were rounded and may not add up to 100%.